These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 25780909

  • 1. AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.
    Choi YJ, Kim SY, So KS, Baek IJ, Kim WS, Choi SH, Lee JC, Bivona TG, Rho JK, Choi CM.
    PLoS One; 2015; 10(3):e0119832. PubMed ID: 25780909
    [Abstract] [Full Text] [Related]

  • 2. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
    Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK, Yoon SJ, Park BM, Park E, Bae JH, Choi CM, Lee JC.
    Cancer Res; 2014 Jan 01; 74(1):253-62. PubMed ID: 24165158
    [Abstract] [Full Text] [Related]

  • 3. AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.
    Yang YM, Jang Y, Lee SH, Kang B, Lim SM.
    Lung Cancer; 2020 Aug 01; 146():70-77. PubMed ID: 32521387
    [Abstract] [Full Text] [Related]

  • 4. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
    Hashida S, Yamamoto H, Shien K, Ohtsuka T, Suzawa K, Maki Y, Furukawa M, Soh J, Asano H, Tsukuda K, Miyoshi S, Kanazawa S, Toyooka S.
    Oncol Rep; 2015 Mar 01; 33(3):1499-504. PubMed ID: 25607753
    [Abstract] [Full Text] [Related]

  • 5. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Kato Y, Ninomiya K, Ohashi K, Tomida S, Makimoto G, Watanabe H, Kudo K, Matsumoto S, Umemura S, Goto K, Ichihara E, Ninomiya T, Kubo T, Sato A, Hotta K, Tabata M, Toyooka S, Maeda Y, Kiura K.
    Cancer Sci; 2018 Oct 01; 109(10):3149-3158. PubMed ID: 30053332
    [Abstract] [Full Text] [Related]

  • 6. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
    Yoshida T, Okamoto I, Okamoto W, Hatashita E, Yamada Y, Kuwata K, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
    Cancer Sci; 2010 Jan 01; 101(1):167-72. PubMed ID: 19804422
    [Abstract] [Full Text] [Related]

  • 7. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
    Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG.
    Nat Genet; 2012 Jul 01; 44(8):852-60. PubMed ID: 22751098
    [Abstract] [Full Text] [Related]

  • 8. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
    Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y.
    Mol Cancer Ther; 2016 Dec 01; 15(12):3040-3054. PubMed ID: 27612490
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.
    Mol Cancer Ther; 2012 Oct 01; 11(10):2149-57. PubMed ID: 22844075
    [Abstract] [Full Text] [Related]

  • 12. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
    Xiong R, Sun XX, Wu HR, Xu GW, Wang GX, Sun XH, Xu MQ, Xie MR.
    Thorac Cancer; 2020 Jan 01; 11(1):156-165. PubMed ID: 31777195
    [Abstract] [Full Text] [Related]

  • 13. Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.
    Jang WJ, Jung SK, Kang JS, Jeong JW, Bae MK, Joo SH, Park GH, Kundu JK, Hong YS, Jeong CH.
    Cancer Sci; 2014 Oct 01; 105(10):1245-53. PubMed ID: 25117641
    [Abstract] [Full Text] [Related]

  • 14. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.
    Kook E, Lee J, Kim DH.
    Arch Toxicol; 2024 May 01; 98(5):1437-1455. PubMed ID: 38443724
    [Abstract] [Full Text] [Related]

  • 15. RP11-874 J12.4 promotes erlotinib resistance in non-small cell lung cancer via increasing AXL expression.
    Huang S, Zhang J, Wu X, Liang B, Pang N, Yang L, Zhang Z.
    Life Sci; 2024 Aug 15; 351():122849. PubMed ID: 38897346
    [Abstract] [Full Text] [Related]

  • 16. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
    Kim D, Bach DH, Fan YH, Luu TT, Hong JY, Park HJ, Lee SK.
    Cell Death Dis; 2019 May 01; 10(5):361. PubMed ID: 31043587
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D, Santini S, Cardinali B, Papoff G, Lalli C, Samperna S, Fustaino V, Giannini G, Ruberti G.
    PLoS One; 2015 May 01; 10(11):e0143333. PubMed ID: 26580964
    [Abstract] [Full Text] [Related]

  • 19. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.
    Bae SY, Hong JY, Lee HJ, Park HJ, Lee SK.
    Oncotarget; 2015 Apr 30; 6(12):10146-60. PubMed ID: 25760142
    [Abstract] [Full Text] [Related]

  • 20. Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells.
    Tian Y, Zhang Z, Miao L, Yang Z, Yang J, Wang Y, Qian D, Cai H, Wang Y.
    Oncol Res; 2016 Apr 30; 24(5):295-303. PubMed ID: 27712586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.